NTRC expands OncolinesProfiler™ reference compound database to 162 anti-cancer agents
New compounds include Herceptin® (trastuzumab), the antibody drug conjugate Kadcyla®, the SUMOylation inhibitor ML-792, and the selective BTK inhibitor acalabrutinib.
Read more
Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer
Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab
Read more
Pivot Park is one of the fastest growing campuses in the Netherlands
Met een groei van 57% aan werkgelegenheid tussen 2014 en 2018 behoort het Pivot Park tot de sterkst groeiende campussen in Nederland.
Read more
Binding term sheet for allogeneic CAR-NK therapies
MolMed and Glycostem announce the execution of a binding term sheet for the development and manufacturing of allogeneic CAR-NK therapies.
Read more
A cup of coffee with … Kelly Knaapen-Arts
Arnold & Siedsma was one of the first companies that became part of the Pivot Park community in 2012.
Read more
New at Pivot Park – GlycoMScan
Recently GlycoMScan has opened their company’s doors in the van Leeuwenhoek building’s basement. GlycoMScan offers services in mass spectrometry, from screening of small molecules to absolute quantification in complex biological matrices.
Read more
New Dutch Q fever test comes out on top in Australian research
The Q-detect™ test, developed by the Dutch Innatoss, turns out to be the best test by far for Q fever screening. The results were presented at the European microbiology conference ECCMID in Madrid.
Read more
Glycostem moves into new lab, production and HQ facility
Glycostem relocated to its new facilities at Pivot Park, Oss, Netherlands. Collectively comprising nearly 500 square meters, the premises include the company’s stateof-the-art laboratory, production facility and administrative HQ.
Read more
NTRC expands SynergyFinder™ platform with triple combination testing
NTRC’s SynergyFinder™ platform allows parallel in vitro screening of combinations and distinguishes additive from synergistic effects.
Read more